It is currently Fri Feb 24, 2017 11:40 am

News News of Gilenya

Site map of Gilenya » Forum : Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Gilenya shown to benefit neurons

The immune system-suppressing multiple sclerosis (MS) drug Gilenya also has potentially beneficial effects on the nervous system, according to a recent study...Read more - http://www.ms-uk.org/MSnews
Read more : Gilenya shown to benefit neurons | Views : 753 | Replies : 0


Anyone carry the JC virus and take Gilenya?

Hi all! I've been taking Aubaggio for the last few years, but my neurologist wants me to switch meds as I've had two relapses in the last two years. He is suggesting Gilenya - but I've just been reading about the PML cases, and I've been tested for the JC Virus in the past and my result was positive. Is anyone else in the same boat? Did you decide to take the risk, or did ...
Read more : Anyone carry the JC virus and take Gilenya? | Views : 1023 | Replies : 1


ponesimod (or gillenia) effects

I have been proposed to try to take part in ponesimod clinical trial, third phase (without placebo). Ponesimod is a drug made by Actellion, the Swiss pharmaceutical company. That is a drug close to gilenia and RPC1063. they all three sequester lymphocytes into lymph nodes.

Does it worth it? Is gilenia really effective drug? What is the estimated rate of disability slowing? What side effects have to be aware of?
Read more : ponesimod (or gillenia) effects | Views : 1369 | Replies : 1


Patients treated with Gilenya “show benefits”

New research evaluating Gilenya’s clinical efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS) has largely supported its use, finding the oral drug’s efficacy in a real-world setting was comparable to results observed in Phase 3 clinical studies...Read more - http://www.ms-uk.org/MSnews
Read more : Patients treated with Gilenya “show benefits” | Views : 1089 | Replies : 1


Generic Gilenya rival launched in Russia

Russian firm BioIntegrator says it has successfully launched Neskler -- the first generic version of Gilenya...Read more - http://www.ms-uk.org/MSnews
Read more : Generic Gilenya rival launched in Russia | Views : 1032 | Replies : 1


Gilenya ‘prevents activation of key immune cells’

In a recent study entitled Myeloid Cells As Target Of Gilenya Action In Multiple Sclerosis, a team of scientists investigated the impact of MS treatment Gilenya on the reactivity of myeloid cells, a key group that comprises several immune cells that are activated in MS patients and the underlying cause of the condition. The study was published in the journal Neurology...Read more - http://www.ms-uk.org/MSnews
Read more : Gilenya ‘prevents activation of key immune cells’ | Views : 1228 | Replies : 0


No conclusions over best drug for Multiple Sclerosis

Two studies - one from France, the other from Denmark - came to conflicting conclusions about whether Tysabri or Gilenya offers better efficacy, researchers have reported here... Read More - http://www.ms-uk.org/MSnews
Read more : No conclusions over best drug for Multiple Sclerosis | Views : 1322 | Replies : 0


Long-term efficacy of Gilenya reinforced by new analysis

Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya. The analysis evaluated the proportion of Gilenya patients with relapsing-remitting multiple sclerosis (RRMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years... Read More - http://www.ms-uk.org/MSnews
Read more : Long-term efficacy of Gilenya reinforced by new analysis | Views : 1110 | Replies : 0


Gilenya found to be effective ‘for up to three years’

An encouraging new analysis reveals Gilenya is an effective MS therapy for a treatment period of up to three years. The results were presented at the Annual Meeting of the Consortium of MS Centres in America... Read More - http://www.ms-uk.org/gilenya
Read more : Gilenya found to be effective ‘for up to three years’ | Views : 1424 | Replies : 0


Third case of PML reported to Novartis

Novartis has been notified of a third case of progressive multifocal leukoencephalopathy (PML) in a patient with relapsing multiple sclerosis (MS) treated with Gilenya... Read More - http://www.ms-uk.org/gilenya
Read more : Third case of PML reported to Novartis | Views : 1579 | Replies : 0


 

Login  •  Register


Statistics

Total posts 236342 • Total topics 25607 • Total members 16906


Contact us | Terms of Service